The aim of the present paper was to examine the correlation between serum concentrations of 12 soluble biological markers and stages of myeloma evaluated according to the Durie-Salmon (D-S) and International Prognostic Index (IPI) stratification systems.
INTRODUCTION
Multiple myeloma (MM) is an unusually heterogeneous B-cell malignancy with an individually different clinical course, characterised by uncontrolled proliferation and progressive accumulation of plasma cells that selectively infiltrate the bone marrow (BM). This devastating cancer results from a high tumor burden with accompanying cytokine dysregulation, osteolytic bone disease and from deposition of high levels of immunoglobulin light chain 1 . The disease progression of MM is characterised by monoclonal plasma cell proliferation, dissemination and vascular circulation of plasma cells, and loss of programmed cell death leading to the accumulation of tumor cells 2 . The crucial role of the BM microenvironment and its ability to support the proliferation of tumour cells are currently being intensively investigated 3 . The adhesion of myeloma cells to BM stromal cells leads to the production of cytokines that support the growth of plasma cells and prevents them from apoptosis. The major plasma cell growth factors secreted are interleukin-6 (IL-6) and its soluble receptor (IL-6/sIL-6R) 4 . Neovascularisation and interactions between plasma cells and osteoclasts resulting in osteoclast activation are two important additional processes contributing to MM pathogenesis and its clinical manifestation. Vascular endothelial growth factor (VEGF) has several biological effects in MM pathogenesis. It modulates the activity of nuclear factor-κB (NF-κB), increases the resorption activity of osteoclasts, and has an impact on proliferation, migration and survival of myeloma cells. Moreover, it may account for the increased microvessel density observed in the BM [5] [6] [7] . Hepatocyte growth factor (HGF) produced by myeloma cells is a pleiotropic cytokine which promotes tumor cell growth, bone marrow dissemination, inhibits osteoblast function and contributes to myeloma bone disease and BM angio- 8 . Migration and invasion of myeloma cells require the secretion of metaloproteinase-2 (MMP-2) and MMP-9 which are possibly modulated, in part, by syndecan-1 (CD 138 ), expressed in plasma cells and which can be shed from the surface of myeloma cells and circulate as soluble factor 9, 10 . The main regulator of osteoclast formation in MM is the receptor of nuclear factor κ-B ligand (RANKL) while osteoprotegerin (OPG) blocks this resorption process. Fas-L overexpression by myeloma cells reflects their high degree of malignancy while abnormal overexpression of apoptogenic receptors such as Fas-L defines the major malignant phenotype associated with progression of MM 11, 12 . As clinically oriented publications deal only sporadically with the relationship between soluble biological substances and clinically advanced MM stages, the purpose of our study was analysis of relationship between 12 soluble markers that characterise osteogenic, angiogenic and other biologically important substances and MM clinical stages (stage 1-3) evaluated according to the Durie-Salmon (D-S) 13, 14 and International Prognostic Index (IPI) 15 and comparison of these two systems which are used in the pathobiology of this disease.
PATIENTS AND METHODS
The analyzed group of 179 multiple myeloma patients diagnosed according to the criteria of International Myeloma Working Group (IMWG) was examined before initiation of treatment from 2004-2008 14, 16 . The median age of the cohort study was 64 years (range 29-90), with M/F ratio 1.2; 65.5% cases of IgG, 21% IgA, 12% BenceJones (B-J) production only, 1% nonsecretory, 0.5% of IgD, the serum monoclonal light chain was κ in 63% and λ in 36%. Patients were staged according to D-S clinical staging system 13 and IPI
15
.
The detection of β 2 -m serum level was performed by Immulite 1000 (Siemens Medical Solutions Diagnostics, normal range 0.1-2.5 mg/l), thymidinekinase (sTK) serum level by a radioenzymoassay (REA kit, Immunotech Prague, normal range 0-10 U/l). The evaluation of sIL-6R (soluble interleukin-6 receptor, 10-90 ng/ml), sVCAM-1 (vascular cell adhesive molecule-1, 395-714 ng/ml), sI-CAM-1 (soluble intercellular cell adhesive molecule-1, 269-691 ng/ml) was performed by commercially available sandwich immunoassays (enzyme-linked immunosorbent assay, ELISA kit, Immunotech Prague), sICTP ( carboxy-terminal telopeptide of type-I, 0.3-6.0 μg/l, ELISA kit, Orion Diagnostica Espoo, Finland), sOPG (soluble osteoprotegerin 1.8-6.4 pmol/l, ELISA kit Bio Vendor GmbH), sPINP (N-terminal telopeptide of type-1 collagen, above 50 years 16.3-73.9 ug/l, modular Cobas 6000, Roche Diagnostics). Analysis of serum concentration of sHGF (hepatocyte grow factor, 671-1992 pg/ml), sVEGF (vascular endothelial growth factor, 62-707 pg/ ml), syndecan-1/sCD 138 (37-123 ng/ml) and sFas (4792-17150 pg/ml) was performed with the help of quantitative sandwich enzymatic immunoassays (Quantikine RD kit, Minneapolis). Measurements were performed according to the manufacturer's instructions, in duplicate and were reproducible. The use of serum from patients for cytokine measurements was approved by the local ethics committee.
The patients' data were analyzed using the KruskalWallis or Mann-Whitney test, as appropriate, p-values < 0.05 were considered statistically significant.
RESULTS
The analysis showed that in the group of 179 patients with diagnosed MM before chemotherapy most frequent were elevated serum levels of β 2 -m, less frequent were sICTP, sIL6R, sVCAM-1, sSyndecan-1/CD 138 a sTK, while pathological values of sOSP, sHGF, sPINP occurred in less than half of patients; only 10 and 4.5% of patients had pathological values of sVEGF and sFas (Fig. 1) .
Stratification according to D-S revealed most frequently the stage III (56%), while stage II and I in 28 and 17%, substage B (patients with S-creatinine level > 170 μmol/l) occurred only in 24% ( Table 1 ). The occurrence of pathological values of evaluated parameters in the whole analyzed group divided into 3 clinical stages (stage I-III) and 2 substages (substage A-B) was as follows: β 2 -m: stage I -43%, stage II -78%, stage III -95%, substage A -75%, substage B -100%; sTK: I-13%, II-48%, III-69%, A-51%, and B-63%; sIL-6R: I-65%, II-56%, III-78%, A-66% and B-79%; sICAM-1: I-7%, II-29%, III-33%, A-25% and B-32%; sVCAM-1: I-72%, II-77%, III-64%, A-68% and B-76%; sICTP: I-33%, II-67%, III-82%, A-60% and B-97%; sPINP: I-13%, II-27%, III-34%, A-28% and B-33%; sOSP: I-32%, II-31%, III-53%, A-37% and B-65%; sHGF: I-17%, II-32%, III-47%, A-29% and B-64%; sVEGF: I-17%, II-12%, III-4%, A-10% and B-5%; sCD 138 (syndecan-1): I-26%, II-60%, III-71%, A-52% and B-86%; sFas: I-0%, II-2%, III-6%, A-3% and B-8%. A complex analysis of all 12 parameters 
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The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems for all 3 stages of MM (I-III) revealed highly significant differences (p < 0.0001) for β 2 -m, sTK, sICTP, and syndecan-1, less important differences in the case of sOSP, sHGF and sVEGF while for the remaining 5 parameters the levels were not statistically significant (Table 1) . Separate analysis of the differences among all clinical stages (I-III) revealed statistically significant differences only in β 2 -m and sTK and between stages II vs. III and I vs. III only in sICTP and I vs II and I vs III in sCD 138 (syndecan-1). In 2 other markers, i.e. in sHGF and sVEGF statistically significant differences were found only in patients with initial, asymptomatic MM phase (stage I) and most advanced phase of disease (stage III). No statistically significant difference was found between stages I-III in case of sIL-6R, sICAM-1, sVCAM-1, sPINP, sOSP and sFas. There were statistically significant differences between patients with present and absent disorders of renal function, i.e. between substage A and B, only in case of β 2 -m, sTK, sICTP, sOSP, sHGF, sSyndecan and sFas, while sIL-6R, sICAM-1, sVCAM-1, sPINP and sVEGF was negative (Table 3) . The IPI stratification system revealed the most frequent presence of category 3 (55%), less frequent was category 2 (28%) and the least frequent was category 1 (17%). The occurrence of pathological values of analyzed parameters in the group divided into 3 prognostic categories according to IPI is given in Fig. 1 . A complex comparison of all 12 analyzed markers in all 3 prognostic MM categories (1-3) showed highly significant differences (p< 0.0001) for β 2 -m, sTK and sICTP, less significant differences for sIL-6R, sVCAM-1, sPINP, sOSP, syndecan-1 and sFas, while in the remaining 2 parameters, sICAM-1 and sVEGF, serum levels did not differ statistically significantly (Table 2) . Statistically significant differences between all categories (1-3) were found only for β 2 -m, sTK and sICTP, between stages 2 vs 3 and 1 vs 3 in case of sHGF. In other 4 markers, sPINP, sOSP, syndecan-1 and sFas, significant differences were found only between category 1 (with most favourable prognosis) and category 3 (patients with worse prognosis). No statistically significant relationship between serum concentration and clinical stage of the disease was found with sIL-6R, sICAM-1, sVCAM-1 and sVEGF (Table 3) .
DISCUSSION
The analysis confirmed that many of the evaluated biological markers connected to the pathobiology of MM are at the time of diagnosis related to the volume of the tumour mass, i.e. to MM progression. Therefore it is not surprising that all evaluations confirmed a close relationship between the key prognostic marker, which is the basic criterion of all recent stratification systems in MM, namely β 2 -m and individual stages of the disease and state of renal function 15, 17 . Increase in β 2 -m in MM is due not only to enhanced synthesis and turnover at the level of cell membranes but also to intensified cell death. Its level is related to disease progression and the state of renal function and moreover to disease activity and internal biological processes in myeloma tissue and activation grade of T and B cell systems. Highly favourable was also the evaluation of the relationship between sTK level which is the marker with important prognostic potential to individual stages of the disease 18 . This finding is not surprising given that the level of sTK expresses a complex proliferation capacity and mass of myeloma cells. Therefore, it is part of one prognostic stratification system 17, 18 . Evaluation of the circulating form of sIL-6R was made with respect to the key position of the IL-6/IL-6R complex in interaction with the signal gp130 molecule, its role in activation of mitogen-activated protein kinase (MAPK) and activation of phosphatidylinositol 3-kinase (PI3K/Akt) pathway, which is closely related to proliferation and apoptosis of myeloma cells. We have already demonstrated the relationship between sIL-6R and MM activity, stage and prognosis 19, 20 . The presented evaluation did not prove, except a complex evaluation of the group according to IPI, any relationship between sIL-6R level and individual MM stages. This supports conclusions of our previous analysis, which did not reveal prognostic importance of sIL-6R levels in the serum of peripheral blood and bone marrow 17 . The rationale for evaluating the relationship with sVCAM-1 and sICAM-1 was based on the known role of both cytoadhesive molecules in the process of bone marrow invasion by myeloma cells, their effect on proliferation and survival of myeloma cells in the microenvironment of bone marrow, and in the process of their extramedular dissemination 21 . Despite the previously 279
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demonstrated relationship between both molecules and some key markers of MM (e.g.. sVCAM-1 vs sIL-2R, sIL-6R and sTNF-α), their relationship to myeloma progression was not proved in the present study 22 . Highly important was the finding of a significant relationship between all MM stages (I-III) and substage B (according to D-S) and serum concentration of sICTP, one key and highly sensitive parameter of bone metabolism in MM. It is known that sICTP levels are closely related to the grade of osteoclastic bone degradation 23 , but sICTP serum level increases also at renal insufficiency 24 .
A close relationship between sICTP and MM progression and especially MM prognosis is certainly associated with this circumstance 23 . Even previous studies have shown that sICTP levels are related to the intensity of bone pain, number and severity of osteolytic lesions and bone fractures, i.e. the signs of progression of myeloma bone disease 23, 25 . This study as well as another study dealing with the same issue showed a very close relationship between sICTP levels and stages 1-3 and substage B of DurieSalmon staging 25 . Our results moreover revealed a very close relationship with prognostic criteria (1-3) within IPI stratification. It appears that sICTP as an easy methodological and economical marker provides clear information about the presence of a very early skeletal myeloma lesion, which can be detected only by means of MRI but not by conventional radiography of the skeleton 26 . ICTP may be also used not only for evaluation of MM progression and activity, but also for the prediction of skeletal damage, and bone disease progression in MM 27 . In accordance with sporadic previous studies, evaluation of serum levels of sPINP correlated with the grade of osteoblastic activity and bone neoplasms 23, 25 . Serum levels of PINP in individual stages of the disease (I-III according D-S) did not differ, the only significant difference being between stage 1 and 3 according to IPI, which can be explained by paradoxical increase due to reparatory activation of osteoblasts caused by microfractures. Neither relationship between serum concentrations of sPINP and expressed disorder of renal function was proved 23, 25 . OSP, acting as a decoy receptor antagonist for receptor activator of nuclear factor κ-B ligand (RANKL) is produced by osteoblasts and stromal cells. Our previous study revealed that the progression of MM and myeloma bone disease depends on the balance between RANKL and OPG, which is of major importance in bone homeostasis. Involvement of the skeleton is associated with enhanced production of RANKL in the microenvironment of bone marrow and decreased secretion of OPG leading to decreased activity and reduced quantity of osteoblasts. Earlier analyses have shown that in MM the serum activity of sOPG is lower than in healthy persons 28 . In contrast to the previous study 29 , but in harmony with another similar study 30 , our analysis showed that MM progression is not associated with decreased serum levels of sOSP, exceptional was only the difference between stage 1 vs 3 according to IPI. In harmony with previous experience, significant relationship between sOPG level and disorder of renal function, i.e. the presence of substage B according to D-S was confirmed 29 . It is evident that isolated evaluation of sOPG serum levels without simultaneous determination of RANKL level is ineffective. Potentially valuable for clinical practice is, according to actual data, the evaluation of RANKL/OPG index, much more suitable for determination of the state of RANKL/OPG or other functionally related merkers, e.g. DKK-1 protein, macrophage inflammatory protein-1 (MIP-1α), MIP-1β, IL-3, IL-1β, stromal derived factor-1 (SDF-1α), frizzled-related protein-2 (sFRP-2) 31 . In harmony with studies reporting on elevated sHGF in MM in 30-50%, we found elevation of sHGF, this pleiotropic multifunctional cytokine playing a crucial role in MM biology (activation of osteoclastic resorption, inhibition of osteoblastic neoplasm, stimulation of neoangiogenesis and proliferation as well as mobilization of myeloma plasmocytes) in 38% (ref. 10, 31, 32 ). Similarly to Sugimura 33 , we observed significantly higher values of sHGF in patients with elevated creatinine, in our study in substage B according to D-S. The proved negative relationship between elevated serum levels of sHGF and prognosis 10 is explained also by a repeatedly proved significant dependence on MM progression because significant relationship of sHGF levels measured by us was proved, similarly to previous study, using both stratification systems (D-S and IPI) when comparing the initial MM stage (stage I) and the most advanced stage (stage III) and in case of IPI also when comparing stage 2 vs 3(ref. 34 ). This finding supports the preceding fact that sHGF level has an inverse relation to the level of serum albumin, a crucial criterion of IPI together with β 2 -m 34 . The importance of HGF role in MM pathobiology is supported by the finding of its high levels in active, progressive form of the disease 32 and decreased levels in favourable therapeutical response 10 . Recent studies indicate that sVEGF, this highly potential angiogenic peptide is involved not only in acceleration of angiogenesis, but also in MM progression, progression of myeloma bone disease and therapeutical resistance 5 , after successful chemotherapy its level decreases 35, 36 . Our analysis showed a suprising tendency to decrease of sVEGF serum levels with advanced stages of the disease, i.e. I-III and in substage B compared to A (according to D-S) and advanced prognostic index 1-3 (according to IPI). However, the found differences were statistically insignificant except a complex evaluation and difference I vs III (according to D-S). Although the missing significance of differences is in harmony with the study of Sezer 36 , but discrepant from studies proving relationship between sVEGF levels and activity and progression grade of MM (difference between stage III vs I+II) 34, 35 . The above facts indicate that the follow-up of sVEGF serum levels is of limited importance for evaluation of myeloma mass volume in the organism. It is known that syndecan-1 (sCD 138 ) a heparan sulphate proteoglycan, expressed on and actively shed from the surface of most myeloma cells. Syndecan-1(sCD 138 ), multifunctional regulator of myeloma pathobiology mediates cell-cell adhesion, induces apoptosis and inhibits growth of myeloma tumor cells and also modulates myeloma bone disease by inhibiting osteoclast formation and promoting osteoblast differentiation, it may also mobilize cytokines a.g. HGF 37 .
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V. Scudla, T. Pika, M. Budikova, P. Petrova, J. Bacovsky, K. Srovnalik, J. Minarik, K. Langova Syndecan-1 is also present in the myeloma microenvironment and acts to promote aggressive myeloma behaviour. Previous studies have demonstrated elevated levels of syndecan-1 in the serum of patients with MM and proved its negative prognostic importance and strong correlation between increased level of serum sCD 138 and tumour mass, as assessed by percent of bone marrow plasmacytosis (BMPC), β 2 -m and MM activity 38, 39 . High levels of sCD 138 correlate with tumour mass and have a significant impact on the biology of MM by virtue of its pleiotrophic effects on the cell behaviour 38 . The occurrence of enhanced serum levels of syndecan-1 in MM varies from 35% (ref. 38 ) to 79% in the literature 9 , in our group elevated values were found in 61% of patients. Although our complex analysis revealed statistically significant relationship to tumour mass volume, a detailed analysis showed statistically significant differences especially when comparing stage 1 vs 2 and 1 vs 3, also in substages A vs B. This finding support previous studies reporting statistically significant relationship between levels of syndecan-1 and values of β 2 -m, BMPC (%), serum of M-protein level 38, 40 , or B-J urie/24 hrs, and levels of sIL6R, sICTP, and stage of MM progression evaluated according to D-S 9, 10, 19 . However, our conclusions are discrepant from studies that did not record relationship between serum levels of syndecan-1 and the volume of tumour mass 41, 42 . Surprising was our finding of only statistically limit difference of serum levels of syndecan-1 during complex evaluation of all three prognostic categories according to IPI and at tagetted comparison of index 1 vs 3. This finding appears exceptional with respect to previous numerous studies proved a significant relationship between serum levels of syndecan-1 and levels of β 2 -m 9,38,39,40 and MM prognosis MM 9, 39, 42, 43 . Thus, serum levels of syndecan-1 do not clearly reflect tumour load and renal failure, nor many other biological aspects of the disease 9, 10 . Our study indicates that evaluation of serum levels of sCD 138 is not a reliable marker for assessment of tumour mass volume especially due to the actually prevailing stratification system according to IPI. The both overexpression and secretion of Fas-L by a number of myeloma cell clones reflect a high degree of malignancy 44 . By measuring Fas-L in plasma cells showed that this receptor occured at high levels in severely anemic MM patients and in some patients with stage III MM 11 . Soluble Fas level in the serum was increased in patients with agressive non-Hodgkins lymphoma and was independent prognostic factor 45 . But analysis of serum levels in our group showed that elevated levels of sFas were present only in 4.5% of patients and concentrations in stages I-III (according to D-S) were highly similar. Statistically significant difference was evident only when comparing substages A vs. B, which indicates depedence of serum levels on the state of renal function. Stratification of patients according to IPI showed different values only between prognostic category 1 and 3. It is concluded that analysis of serum levels of sFas is of no practical importance in MM.
CONCLUSIONS
The present study concludes that of a large scale of examined angiogenic cytokines, osteogenic markers and other biological parameters, good, statistically significant and useful for clinical practice were only serum levels of β 2 -m, sTK, sICTP and partly syndecan-1(sCD 138 ) and sHGF. The found relationships contribute to better knowledge of pathobiology of multiple myeloma. This study is to be completed by future, more extensive analysis of their mutual relationship, difference from MGUS and assessment of their prognostic potential. 
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